HCAR2 and myeloid sarcoma: Notably, HCAR2 is required for the therapeutic efficacy of DMF in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, and in two mouse models of inflammatory skin diseases (Chen et al., 2014; Suhrkamp et al., 2022; Wannick et al., 2018).